What is ADAPTIMMUNE THERAPTCS's earnings per share (EPS)?

ADAPTIMMUNE THERAPTCS (ADAPY) reported diluted earnings per share of -$0.05 for fiscal year 2024. This represents a 44.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ADAPTIMMUNE THERAPTCS (ADAPY) Financials

ADAPY

Trailing 12 months to June 30, 2025

Revenue $65.1M -54.0% YoY

Net Income -$169.8M -134.1% YoY

EPS (Diluted) -$0.11 -120.0% YoY

Free Cash Flow -$191.7M -316.4% YoY

Market Cap $8.0M as of Oct 14, 2026

Price / Sales 0.1x on $65.1M revenue, trailing 12 months to June 30, 2025

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2025

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2025, ended Jun 30, 2025 Reported Aug 13, 2025 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2025, filed Aug 13, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ADAPY SEC filings page.

ADAPTIMMUNE THERAPTCS (ADAPY) reported $65.1M in revenue over the twelve months to Jun 30, 2025, down 54.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ADAPY FY2024 2026-10-04

Revenue has scaled sharply, but research spending still outruns operating economics, leaving external financing central to the business model.

From FY2023 to FY2024, revenue increased 195.3% while operating loss narrowed 50.8%, showing that added revenue is beginning to absorb fixed costs rather than merely enlarging losses. Yet R&D rose to $149M even as the net loss remained $70.8M, so the improvement reflects operating scale alongside continued development spending, not a completed earnings model.

The reported 100.0% gross margin is less informative than the cost structure: cost of revenue was only $70K. R&D and SG&A together reached $236M, meaning profitability is currently determined by development and corporate spending rather than production costs.

Operating cash flow of -$73.2M nearly matched free cash flow of -$74.1M, indicating capital spending made little difference to cash use. Financing provided $78.7M in FY2024, while reported cash, equivalents, and investments equaled 24.9 months of the latest annual operating outflow, linking liquidity to financing activity rather than internally generated cash.

Financial Health Signals

Financial health score not available

ADAPTIMMUNE THERAPTCS does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-5.80

ADAPTIMMUNE THERAPTCS scores -5.80, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($8.0M) relative to total liabilities ($234.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/7

ADAPTIMMUNE THERAPTCS passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

ADAPTIMMUNE THERAPTCS reported a net loss of $70.8M while operations used $73.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

ADAPTIMMUNE THERAPTCS reported an operating loss of $68.8M against $3.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$13.7M

YoY-89.3%

QoQ+87.7%

5Y CAGR+93.7%

ADAPTIMMUNE THERAPTCS generated $13.7M in revenue in Q2 2025. This represents a decrease of 89.3% from the same quarter a year earlier. Against the prior quarter it is up 87.7%.

EBITDA

-$28.0M

YoY-139.2%

QoQ+35.6%

ADAPTIMMUNE THERAPTCS's EBITDA was -$28.0M in Q2 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 139.2% from the same quarter a year earlier. Against the prior quarter it is up 35.6%.

Net Income

-$30.3M

YoY-143.6%

QoQ+36.2%

ADAPTIMMUNE THERAPTCS reported -$30.3M in net income in Q2 2025. This represents a decrease of 143.6% from the same quarter a year earlier. Against the prior quarter it is up 36.2%.

EPS (Diluted)

-$0.02

YoY-150.0%

QoQ+33.3%

ADAPTIMMUNE THERAPTCS earned -$0.02 per diluted share (EPS) in Q2 2025. This represents a decrease of 150.0% from the same quarter a year earlier. Against the prior quarter it is up 33.3%.

Cash & Balance Sheet

Free Cash Flow

-$34.9M

YoY-174.2%

QoQ+48.6%

ADAPTIMMUNE THERAPTCS recorded an outflow of $34.9M in free cash flow in Q2 2025, representing a cash shortfall after capex. This represents a decrease of 174.2% from the same quarter a year earlier. Against the prior quarter it is up 48.6%.

Cash & Debt

$26.1M

YoY-87.7%

QoQ-36.5%

5Y CAGR-26.6%

10Y CAGR-19.5%

ADAPTIMMUNE THERAPTCS held $26.1M in cash against $25.7M in long-term debt as of Q2 2025.

Shares Outstanding

1.59B

YoY+3.6%

QoQ0.0%

5Y CAGR+11.4%

ADAPTIMMUNE THERAPTCS had 1.59B shares outstanding in Q2 2025. This represents an increase of 3.6% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q2 2025.

Margins & Returns

Gross Margin

81.7%

QoQ-6.2pp

ADAPTIMMUNE THERAPTCS's gross margin was 81.7% in Q2 2025, indicating the percentage of revenue retained after direct costs. Against the prior quarter it is down 6.2 percentage points.

Operating Margin

Not shown for Q2 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q2 2025.

Capital Allocation

R&D Spending

$23.0M

YoY-43.2%

QoQ-20.4%

5Y CAGR+2.3%

ADAPTIMMUNE THERAPTCS invested $23.0M in research and development in Q2 2025. This represents a decrease of 43.2% from the same quarter a year earlier. Against the prior quarter it is down 20.4%.

Capital Expenditures

$75K

YoY-82.2%

QoQ-93.8%

5Y CAGR-22.5%

ADAPTIMMUNE THERAPTCS invested $75K in capex in Q2 2025, funding long-term assets and infrastructure. This represents a decrease of 82.2% from the same quarter a year earlier. Against the prior quarter it is down 93.8%.

Share Buybacks

Not reported for Q2 2025.

ADAPY Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ADAPY quarterly income statement

Metric	TTM	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	$65.1M	$178.0M+195.3%	$60.3M+122.0%	$27.1M+341.5%	$6.1M+55.4%	$4.0M+252.8%	$1.1M-98.1%	$59.5M+57.3%	$37.8M+166.5%	$14.2M+43.8%	$9.9M+1096.5%	$825K	N/A
Cost of Revenue	N/A	$70K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	$178.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$125.2M	$149.1M+17.8%	$126.5M-1.0%	$127.7M+15.0%	$111.1M+21.3%	$91.6M-6.1%	$97.5M-0.8%	$98.3M+12.5%	$87.4M+37.0%	$63.8M+164.3%	$24.1M+152.1%	$9.6M+27.8%	$7.5M
SG&A Expenses	$90.2M	$87.3M+18.7%	$73.5M+16.0%	$63.4M+10.6%	$57.3M+25.1%	$45.8M+5.5%	$43.4M-0.5%	$43.6M+40.2%	$31.1M+34.0%	$23.2M+123.7%	$10.4M+274.4%	$2.8M+121.0%	$1.3M
Operating Income	-$164.2M	-$68.8M+50.8%	-$139.7M+14.8%	-$164.0M-1.1%	-$162.2M-21.6%	-$133.4M+4.6%	-$139.8M-69.7%	-$82.4M-2.1%	-$80.7M-10.8%	-$72.8M-195.4%	-$24.6M-113.9%	-$11.5M-31.7%	-$8.7M
EBITDA	N/A	-$57.5M+55.7%	-$129.9M+17.7%	-$157.9M-1.4%	-$155.7M-23.7%	-$125.8M+4.5%	-$131.8M-76.7%	-$74.6M+0.9%	-$75.2M-8.2%	-$69.5M-190.8%	-$23.9M-111.9%	-$11.3M-29.6%	-$8.7M
Interest Expense	N/A	$3.3M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$3.7M	$3.6M+167.7%	$1.3M-46.5%	$2.5M+215.7%	$791K+388.3%	$162K-33.1%	$242K-51.3%	$497K+10.2%	$451K-49.4%	$892K+265.6%	$244K+225.3%	$75K	N/A
Net Income	-$169.8M	-$70.8M+37.8%	-$113.9M+31.2%	-$165.5M-4.7%	-$158.1M-21.5%	-$130.1M+5.2%	-$137.2M-43.6%	-$95.5M-36.2%	-$70.1M+2.0%	-$71.6M-224.5%	-$22.1M-90.1%	-$11.6M-32.7%	-$8.7M
EPS (Basic)	N/A	-$0.05+44.4%	-$0.09+47.1%	-$0.170.0%	-$0.17-13.3%	-$0.15+31.8%	-$0.22	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.11	-$0.05+44.4%	-$0.09+47.1%	-$0.170.0%	-$0.17-13.3%	-$0.15+31.8%	-$0.22	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	1.51B+25.5%	1.21B+24.7%	967M+3.5%	935M+9.4%	855M+35.7%	630M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q
Revenue	$13.7M-89.3%	$7.3M+28.3%	$3.2M+1294.8%	$40.9M+458.8%	$128.2M+2399.6%	$5.7M-88.1%	$231K-97.9%	$7.3M+4.5%
Cost of Revenue	$2.5M	$879K	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$11.2M	$6.4M	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$23.0M-43.2%	$28.9M-18.0%	$39.1M+17.7%	$34.3M-9.2%	$40.4M+35.0%	$35.2M+37.8%	$33.2M+44.1%	$37.8M+13.9%
SG&A Expenses	$18.5M-3.1%	$23.3M+18.0%	$27.2M+61.0%	$21.3M+31.6%	$19.1M-4.9%	$19.7M-3.3%	$16.9M+10.9%	$16.2M-3.9%
Operating Income	-$30.3M-144.1%	-$45.7M+7.2%	-$73.5M-47.5%	-$14.7M+68.5%	$68.7M+253.0%	-$49.3M-3074.7%	-$49.9M-83.0%	-$46.6M-8.5%
EBITDA	-$28.0M-139.2%	-$43.4M+6.6%	-$70.5M-51.0%	-$12.0M+72.7%	$71.4M+267.0%	-$46.5M-1502.4%	-$46.7M-58.0%	-$43.8M-5.2%
Interest Expense	$962K+82.9%	$1.9M	N/A	$1.1M	$526K	N/A	N/A	N/A
Income Tax	$612K+16.3%	$575K+9.3%	$1.7M+358.1%	$831K+21.0%	$526K-22.6%	$526K-15.8%	-$656K-166.0%	$687K+72.2%
Net Income	-$30.3M-143.6%	-$47.6M+1.9%	-$74.2M-54.9%	-$17.6M+61.4%	$69.5M+425.0%	-$48.5M-4781.8%	-$47.9M-63.8%	-$45.6M-10.1%
EPS (Basic)	-$0.02-140.0%	-$0.030.0%	-$0.05-66.7%	-$0.01+66.7%	$0.05+350.0%	-$0.03	-$0.030.0%	-$0.03+25.0%
EPS (Diluted)	-$0.02-150.0%	-$0.030.0%	-$0.05-66.7%	-$0.01+66.7%	$0.04	-$0.03	-$0.03	-$0.03+25.0%
Diluted Shares (Avg)	1.58B+1.6%	1.54B+6.3%	N/A	1.53B+13.0%	1.56B	1.45B+45.1%	N/A	1.36B+38.4%

ADAPY Balance Sheet

ADAPY quarterly balance sheet

Metric	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$246.0M-13.0%	$282.6M-14.1%	$328.9M-30.0%	$469.5M+4.1%	$451.1M+148.5%	$181.5M-34.4%	$276.7M-1.6%	$281.1M+19.9%	$234.5M-22.0%	$300.7M+439.4%	$55.7M	N/A
Current Assets	$188.2M-9.3%	$207.6M-18.7%	$255.4M-38.5%	$415.5M+4.3%	$398.2M+230.4%	$120.5M-47.9%	$231.1M+0.4%	$230.2M+15.8%	$198.8M-32.6%	$295.1M+443.4%	$54.3M	N/A
Cash & Equivalents	$91.1M-36.7%	$144.0M+33.3%	$108.0M-28.0%	$149.9M+163.6%	$56.9M+12.8%	$50.4M-26.3%	$68.4M-18.6%	$84.0M-47.1%	$158.8M-30.7%	$229.0M+347.5%	$51.2M	N/A
Short-Term Investments	$60.5M+1951.8%	$2.9M-96.9%	$96.6M-56.0%	$219.6M-29.5%	$311.3M+695.6%	$39.1M-71.4%	$136.8M+10.1%	$124.2M	$0	$0	$0	N/A
Inventory	$7.3M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.5M+77.1%	$821K-89.0%	$7.4M+888.7%	$752K+441.0%	$139K	N/A	$192K-6.8%	$206K-86.1%	$1.5M+36900.0%	$4K-97.1%	$138K	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Total Liabilities	$234.1M-3.7%	$243.1M-1.6%	$247.0M-6.3%	$263.6M+139.8%	$109.9M+89.8%	$57.9M+94.0%	$29.9M-61.8%	$78.2M+14.3%	$68.4M+64.2%	$41.6M-21.1%	$52.8M	N/A
Current Liabilities	$64.5M-11.3%	$72.8M+12.8%	$64.5M+3.1%	$62.5M+60.1%	$39.1M+13.8%	$34.3M+40.5%	$24.4M-67.1%	$74.3M+84.5%	$40.3M+50.5%	$26.8M-49.3%	$52.8M	N/A
Non-Current Liabilities	$169.6M-0.4%	$170.3M-6.7%	$182.5M-9.2%	$201.0M+183.8%	$70.8M+200.6%	$23.6M+335.2%	$5.4M+40.7%	$3.8M-86.3%	$28.1M+88.8%	$14.9M	$0	N/A
Long-Term Debt	$50.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$11.8M-70.0%	$39.5M-51.7%	$81.9M-60.2%	$206.0M-39.6%	$341.2M+176.0%	$123.6M-49.9%	$246.9M+21.6%	$203.0M+22.2%	$166.1M-35.9%	$259.0M+8659.0%	$3.0M+237.2%	-$2.2M
Retained Earnings	-$1.1B-6.9%	-$1.0B-12.5%	-$909.3M-22.2%	-$743.8M-27.0%	-$585.8M-28.5%	-$455.7M-43.1%	-$318.5M-37.5%	-$231.6M-43.4%	-$161.5M-141.3%	-$66.9M-122.2%	-$30.1M	N/A

Metric	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q
Total Assets	$130.6M-59.4%	$158.1M-38.7%	$246.0M-13.0%	$317.4M+7.0%	$321.7M-6.2%	$258.0M-10.4%	$282.6M-14.1%	$296.6M-10.7%
Current Assets	$78.1M-69.2%	$103.0M-44.9%	$188.2M-9.3%	$244.2M+11.3%	$253.8M-3.1%	$186.9M-12.6%	$207.6M-18.7%	$219.4M-16.9%
Cash & Equivalents	$26.1M-87.7%	$41.1M-70.8%	$91.1M-36.7%	$116.7M+29.6%	$211.8M+175.2%	$140.7M+17.4%	$144.0M+33.3%	$90.1M+14.0%
Short-Term Investments	$0-100.0%	$18.5M+520.7%	$60.5M+1951.8%	$69.3M-3.2%	$3.0M-97.7%	$3.0M-93.5%	$2.9M-96.9%	$71.7M-40.6%
Inventory	$11.4M	$11.8M	$7.3M	$1.9M	N/A	N/A	N/A	N/A
Accounts Receivable	$9.3M+298.8%	$4.4M-47.9%	$1.5M+77.1%	$12.5M+1484.3%	$2.3M-21.4%	$8.4M+390.0%	$821K-89.0%	$789K-55.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$201.6M-10.6%	$195.5M-16.3%	$234.1M-3.7%	$237.4M+13.9%	$225.4M+4.2%	$233.6M+14.4%	$243.1M-1.6%	$208.5M-4.7%
Current Liabilities	$51.5M-37.2%	$51.1M-23.1%	$64.5M-11.3%	$63.5M-15.6%	$82.1M+7.8%	$66.4M+4.4%	$72.8M+12.8%	$75.1M+13.7%
Non-Current Liabilities	$150.1M+4.7%	$144.4M-13.6%	$169.6M-0.4%	$174.0M+30.5%	$143.4M+2.2%	$167.2M+19.0%	$170.3M-6.7%	$133.4M-12.7%
Long-Term Debt	$25.7M+2.9%	$25.4M	$50.2M	$49.9M	$25.0M	N/A	N/A	N/A
Total Equity	-$71.0M-173.7%	-$37.4M-253.6%	$11.8M-70.0%	$80.0M-9.2%	$96.3M-24.0%	$24.4M-70.9%	$39.5M-51.7%	$88.1M-22.2%
Retained Earnings	-$1.2B-16.9%	-$1.1B-6.5%	-$1.1B-6.9%	-$1.0B-4.6%	-$1.0B-7.8%	-$1.1B-18.0%	-$1.0B-12.5%	-$975.3M-10.8%

Not reported in any period shown, so not listed: Goodwill.

ADAPY Cash Flow Statement

ADAPY quarterly cash flow statement

Metric	TTM	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	-$190.0M	-$73.2M+48.0%	-$140.9M+0.6%	-$141.8M-1421.4%	$10.7M+120.0%	-$53.6M+52.4%	-$112.5M-7.8%	-$104.4M-92.2%	-$54.3M-12.8%	-$48.2M-62.4%	-$29.7M-180.5%	$36.8M+445.1%	-$10.7M
Depreciation & Amortization	N/A	$11.2M+14.1%	$9.8M+62.0%	$6.1M-7.5%	$6.6M-13.5%	$7.6M-5.2%	$8.0M+2.6%	$7.8M+44.0%	$5.4M+65.0%	$3.3M+347.1%	$735K+206.3%	$240K+410.6%	$47K
Stock-Based Compensation	N/A	$12.1M+2.4%	$11.8M-35.5%	$18.2M-11.6%	$20.6M+98.1%	$10.4M-5.8%	$11.1M-31.8%	$16.2M+50.0%	$10.8M+22.5%	$8.8M+24.6%	$7.1M+2031.9%	$332K+86.5%	$178K
Capital Expenditures	$1.6M	$886K-81.1%	$4.7M-84.1%	$29.5M+244.0%	$8.6M+266.3%	$2.3M+47.0%	$1.6M-59.3%	$3.9M-84.1%	$24.6M+114.2%	$11.5M+126.5%	$5.1M+271.9%	$1.4M+718.0%	$167K
Free Cash Flow	-$191.7M	-$74.1M+49.1%	-$145.6M+15.0%	-$171.3M-8047.3%	$2.2M+103.9%	-$55.9M+51.0%	-$114.1M-5.4%	-$108.3M-37.2%	-$79.0M-32.3%	-$59.7M-71.7%	-$34.7M-198.0%	$35.5M+427.2%	-$10.8M
Investing Cash Flow	$1.8M	-$59.0M-133.4%	$176.5M+98.1%	$89.1M+17.6%	$75.8M+127.2%	-$278.9M-393.8%	$94.9M+643.9%	-$17.5M+86.2%	-$126.1M-810.1%	$17.8M+130.2%	-$58.8M	N/A	N/A
Financing Cash Flow	$1.3M	$78.7M+8848.8%	$880K-93.2%	$12.9M+291.3%	$3.3M-99.0%	$340.1M+92810.1%	$366K-99.6%	$102.7M-0.8%	$103.6M+609123.5%	$17K-100.0%	$274.9M	N/A	N/A

Metric	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q
Operating Cash Flow	-$34.8M-173.4%	-$66.6M-108.4%	-$34.2M-133.1%	-$54.5M-20.6%	$47.4M+208.3%	-$31.9M+14.3%	-$14.7M-818.7%	-$45.2M+6.2%
Depreciation & Amortization	$2.3M-13.3%	$2.3M-17.3%	$2.7M-5.3%	$2.7M-4.4%	$2.7M+24.1%	$2.8M+67.0%	$2.8M+222.6%	$2.8M+109.4%
Stock-Based Compensation	$1.3M-56.8%	$669K-78.4%	N/A	$3.1M-4.1%	$3.1M-20.3%	$3.1M+85.1%	N/A	$3.2M-13.1%
Capital Expenditures	$75K-82.2%	$1.2M+1079.4%	$219K-73.5%	$143K-50.5%	$422K-65.3%	$102K-95.7%	$827K-75.8%	$289K-97.1%
Free Cash Flow	-$34.9M-174.2%	-$67.8M-111.5%	-$34.4M-122.0%	-$54.6M-20.1%	$47.0M+204.4%	-$32.1M+19.1%	-$15.5M-1029.1%	-$45.4M+21.9%
Investing Cash Flow	$18.5M+2588.6%	$41.2M+11595.5%	$8.2M-88.0%	-$66.0M-215.2%	-$743K-127.6%	-$358K-100.7%	$68.2M+225.5%	$57.3M+98.6%
Financing Cash Flow	$1.7M-93.3%	-$25.3M-186.6%	$1K-98.6%	$25.0M+4094.8%	$24.5M+174985.7%	$29.2M+14815.8%	$74K-94.7%	$596K-59.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ADAPY Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ADAPY quarterly financial ratios

Metric	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Gross Margin	100.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-38.6%	-231.8%	-604.0%	-2638.6%	-3370.5%	-12457.2%	-138.4%	-213.2%	-512.7%	-249.6%	-1396.5%	N/A
Net Margin	-39.8%	-188.9%	-609.5%	-2571.0%	-3286.8%	-12225.0%	-160.5%	-185.4%	-504.2%	-223.5%	-1406.2%	N/A
Return on Equity	-597.6%-309.4pp	-288.2%-86.1pp	-202.1%-125.3pp	-76.8%-38.6pp	-38.1%+72.8pp	-110.9%-72.2pp	-38.7%-4.1pp	-34.5%+8.5pp	-43.1%-34.6pp	-8.5%+383.8pp	-392.3%	N/A
Return on Assets	-28.8%+11.5pp	-40.3%+10.0pp	-50.3%-16.6pp	-33.7%-4.8pp	-28.8%+46.7pp	-75.6%-41.1pp	-34.5%-9.6pp	-24.9%+5.6pp	-30.5%-23.2pp	-7.3%+13.5pp	-20.8%	N/A
Current Ratio	2.92+0.1x	2.85-1.1x	3.96-2.7x	6.64-3.5x	10.19+6.7x	3.51-5.9x	9.46+6.4x	3.10-1.8x	4.94-6.1x	11.02+10.0x	1.03	N/A
Debt-to-Equity	4.24-1.9x	6.15+3.1x	3.02+1.7x	1.28+1.0x	0.32-0.1x	0.47+0.3x	0.12-0.3x	0.390.0x	0.41+0.3x	0.16-17.7x	17.85	N/A
Asset Turnover	0.72+0.5x	0.21+0.1x	0.08+0.1x	0.010.0x	0.010.0x	0.01-0.2x	0.21+0.1x	0.13+0.1x	0.060.0x	0.030.0x	0.01	N/A
FCF Margin	-41.6%	-241.5%	-630.9%	35.0%	-1413.1%	-10169.3%	-182.0%	-208.7%	-420.3%	-352.0%	4299.3%	N/A

Metric	Q2'2510-Q	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q
Gross Margin	81.7%	87.9%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-221.5%	-627.8%	-2281.8%	-35.9%	53.6%	-867.6%	-21582.7%	-637.1%
Net Margin	-221.8%	-653.2%	-2303.4%	-43.1%	54.2%	-854.2%	-20743.3%	-623.1%
Return on Equity	N/A	N/A	-626.3%-505.1pp	-22.0%+29.7pp	72.2%+89.1pp	-199.0%-200.2pp	-121.3%-85.5pp	-51.7%-15.2pp
Return on Assets	-23.2%-44.8pp	-30.1%-11.3pp	-30.2%-13.2pp	-5.5%+9.8pp	21.6%+27.8pp	-18.8%-19.2pp	-17.0%-8.1pp	-15.4%-2.9pp
Current Ratio	1.52-1.6x	2.02-0.8x	2.92+0.1x	3.85+0.9x	3.09-0.3x	2.81-0.5x	2.85-1.1x	2.92-1.1x
Debt-to-Equity	N/A	N/A	4.24-1.9x	0.62-1.7x	0.26-1.4x	9.59+7.2x	6.15+3.1x	2.37+0.4x
Asset Turnover	0.10-0.3x	0.050.0x	0.010.0x	0.13+0.1x	0.40+0.4x	0.02-0.1x	0.000.0x	0.020.0x
FCF Margin	-254.8%	-930.6%	-1068.4%	-133.5%	36.6%	-564.5%	-6711.3%	-621.0%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Where ADAPTIMMUNE THERAPTCS Ranks

Frequently Asked Questions

What is ADAPTIMMUNE THERAPTCS's annual revenue?

ADAPTIMMUNE THERAPTCS (ADAPY) reported $178.0M in total revenue for fiscal year 2024. This represents a 195.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ADAPTIMMUNE THERAPTCS's revenue growing?

ADAPTIMMUNE THERAPTCS (ADAPY) revenue grew by 195.3% year-over-year, from $60.3M to $178.0M in fiscal year 2024.

Is ADAPTIMMUNE THERAPTCS profitable?

No, ADAPTIMMUNE THERAPTCS (ADAPY) reported a net income of -$70.8M in fiscal year 2024, with a net profit margin of -39.8%.

What is ADAPTIMMUNE THERAPTCS's EBITDA?

ADAPTIMMUNE THERAPTCS (ADAPY) had EBITDA of -$57.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does ADAPTIMMUNE THERAPTCS have?

As of fiscal year 2024, ADAPTIMMUNE THERAPTCS (ADAPY) had $91.1M in cash and equivalents against $50.2M in long-term debt.

What is ADAPTIMMUNE THERAPTCS's gross margin?

ADAPTIMMUNE THERAPTCS (ADAPY) had a gross margin of 100.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is ADAPTIMMUNE THERAPTCS's operating margin?

ADAPTIMMUNE THERAPTCS (ADAPY) had an operating margin of -38.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is ADAPTIMMUNE THERAPTCS's net profit margin?

ADAPTIMMUNE THERAPTCS (ADAPY) had a net profit margin of -39.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is ADAPTIMMUNE THERAPTCS's return on equity (ROE)?

ADAPTIMMUNE THERAPTCS (ADAPY) has a return on equity of -597.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is ADAPTIMMUNE THERAPTCS's free cash flow?

ADAPTIMMUNE THERAPTCS (ADAPY) recorded an outflow of $74.1M in free cash flow during fiscal year 2024. This represents a 49.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ADAPTIMMUNE THERAPTCS's operating cash flow?

ADAPTIMMUNE THERAPTCS (ADAPY) recorded an outflow of $73.2M in operating cash flow during fiscal year 2024, representing cash used by core business activities.

What are ADAPTIMMUNE THERAPTCS's total assets?

ADAPTIMMUNE THERAPTCS (ADAPY) had $246.0M in total assets as of fiscal year 2024, including both current and long-term assets.

What are ADAPTIMMUNE THERAPTCS's capital expenditures?

ADAPTIMMUNE THERAPTCS (ADAPY) invested $886K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does ADAPTIMMUNE THERAPTCS spend on research and development?

ADAPTIMMUNE THERAPTCS (ADAPY) invested $149.1M in research and development during fiscal year 2024.

How many shares does ADAPTIMMUNE THERAPTCS have outstanding?

ADAPTIMMUNE THERAPTCS (ADAPY) had 1.54B shares outstanding as of fiscal year 2024.

What is ADAPTIMMUNE THERAPTCS's current ratio?

ADAPTIMMUNE THERAPTCS (ADAPY) had a current ratio of 2.92 as of fiscal year 2024, which is generally considered healthy.

What is ADAPTIMMUNE THERAPTCS's debt-to-equity ratio?

ADAPTIMMUNE THERAPTCS (ADAPY) had a debt-to-equity ratio of 4.24 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ADAPTIMMUNE THERAPTCS's return on assets (ROA)?

ADAPTIMMUNE THERAPTCS (ADAPY) had a return on assets of -28.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is ADAPTIMMUNE THERAPTCS's P/E ratio?

ADAPTIMMUNE THERAPTCS (ADAPY) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2025). The market capitalization is $8.0M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is ADAPTIMMUNE THERAPTCS's price-to-sales ratio?

ADAPTIMMUNE THERAPTCS (ADAPY) trades at 0.1x sales, its market capitalization divided by revenue of $65.1M revenue, trailing 12 months to June 30, 2025. The market capitalization is $8.0M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does ADAPTIMMUNE THERAPTCS's liquidity compare with its operating cash outflow?

At the end of fiscal year 2024, ADAPTIMMUNE THERAPTCS (ADAPY) held $151.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $73.2M over that year. Dividing the one by the other, the reported balance equals about 25 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is ADAPTIMMUNE THERAPTCS's Altman Z-Score?

ADAPTIMMUNE THERAPTCS (ADAPY) has an Altman Z-Score of -5.80, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is ADAPTIMMUNE THERAPTCS's Piotroski F-Score?

ADAPTIMMUNE THERAPTCS (ADAPY) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ADAPTIMMUNE THERAPTCS's earnings high quality?

ADAPTIMMUNE THERAPTCS (ADAPY) reported a net loss of $70.8M while operations used $73.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can ADAPTIMMUNE THERAPTCS cover its interest payments?

ADAPTIMMUNE THERAPTCS (ADAPY) reported an operating loss of $68.8M against $3.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.